ArticleThe Journal of experimental medicine2001
The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.
Article in The Journal of experimental medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 246 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
246 citing papers in PubMed, 550 citations in OpenAlex.
- OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12-Week Clinical Trial.Journal of cosmetic dermatology · 2025Trial
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis.International journal of molecular sciences · 2026Article
- Bulky pcDNA plasmid encoding Leishmania- and Sandfly-derived antigens resulted in transient Th1 response post Leishmania major infection in BALB/c mice.Scientific reports · 2026Article
- Persistent antigen is essential for sustainingScience advances · 2026Article
- Long pentraxin 3 (PTX3) regulates IL-17A-mediated immunity toFrontiers in immunology · 2026Article
- Mechanisms of Immune Evasion, Dissemination, and Persistence in Leishmania amazonensis Infection.Parasite immunology · 2026Review
- Enhanced Topical Treatment of Cutaneous Leishmaniasis Using Niosomal Gel of Tioxolone-Benzoxonium Chloride: In silico, in vitro, and in vivo Evaluation.Research and reports in tropical medicine · 2026Article
- Article
- Review
- The Capsular Polysaccharides GXM and GXMGal fromMicroorganisms · 2025Article
- Efficacy of LaAg Vaccine Associated with Saponin AgainstVaccines · 2025Article
- Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.Vaccines · 2024Review
- Immunization withVaccines · 2024Article
- ExploitingCells · 2024Article
- Live attenuated-nonpathogenicFrontiers in microbiology · 2024Review
- Memory T cells: promising biomarkers for evaluating protection and vaccine efficacy against leishmaniasis.Frontiers in immunology · 2024Review
- Antigen recognition reinforces regulatory T cell mediated Leishmania major persistence.Nature communications · 2023Article
- Loss of CD4Immunity · 2023Article
- B lymphocytes in COVID-19: a tale of harmony and discordance.Archives of virology · 2023Review
186 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Some pathogens (e.g., Mycobacterium tuberculosis, Toxoplasma gondii, Leishmania spp) have been shown to persist in their host after clinical cure, establishing the risk of disease reactivation. We analyzed the conditions necessary for the long term maintenance of Leishmania major in genetically resistant C57BL/6 mice after spontaneous healing of their dermal lesions. Interleukin (IL)-10 was found to play an essential role in parasite persistence as sterile cure was achieved in IL-10-deficient and IL-4/IL-10 double-deficient mice. The requirement for IL-10 in establishing latency associated with natural infection was confirmed in IL-10-deficient mice challenged by bite of infected sand flies. The host-parasite equilibrium was maintained by CD4+ and CD8+ T cells which were each able to release IL-10 or interferon (IFN)-gamma, and were found to accumulate in chronic sites of infection, including the skin and draining lymph node. A high frequency of the dermal CD4+ T cells released both IL-10 and IFN-gamma. Wild-type mice treated transiently during the chronic phase with anti-IL-10 receptor antibodies achieved sterile cure, suggesting a novel therapeutic approach to eliminate latency, infection reservoirs, and the risk of reactivation disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.